K. Klavdianou, MD, Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany; Department of Rheumatology, "Asklepieion" General Hospital, Voula, Athens, Greece
Auto-generated profile, based on publicly available information
Kalliopi Klavdianou
K. Klavdianou, MD, Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany; Department of Rheumatology, "Asklepieion" General Hospital, Voula, Athens, Greece
Axial SpA (axSpA) is a common rheumatic disease characterized by inflammation leading to bone formation and functional impairment. TNF-α and IL-17 represent established targets in axSpA. TNF-α and IL-17 inhibitors have demonstrated efficacy in clinical trials and are currently approved biologic DMARDs for all subsets of the disease. Several lines of evidence implicate a role of an IL-23–IL-17 axis in the disease pathogenesis. In this light, and given the success of IL-17 blockade in axSpA, a similar good response to IL-23 was anticipated. Nevertheless, two clinical trials of anti-IL-23 monoclonal antibodies in axSpA have clearly exhibited negative results. This failure has raised theories for a degree of IL-23 independent pathway. The Janus kinase (JAK) pathway is also a potential therapeutic target, since several cytokines, including those involved in the IL-23–IL-17 axis, signal through the JAK family of tyrosine kinases. Further studies and more extended evaluation of response to cytokine inhibition across different tissues will be required to improve our understanding of SpA pathogenesis and determine its optimal management.
Pharmacological management in the axial spondyloarthritis (axSpA) field has advanced in recent years. Accumulating evidence on long-term efficacy and safety of biological agents targeting TNFa and IL-17, as well as data on JAK inhibitors is now available. Rheumatologists have currently more options for treatment as compared with 20 years ago, but choosing the best therapeutical approach for a single patient remains a challenge. Despite generalized treatment recommendations provided by international societies, patients present with a heterogeneity of symptoms and treatment responses. In the context of personalized medicine, understanding the disease phenotype in combination with extra-musculoskeletal manifestations is a core step for treatment decision making. Beyond disease-related aspects, comorbidities could also be particularly relevant in the selection of the most appropriate drug, given their different efficacy and safety profiles. AxSpA patient’s fertility and pregnancy outcomes with regard to therapy also form a consideration, since symptom onset usually falls into the child-bearing age. This article will discuss the selective effect of the approved treatment modalities on the different axSpA manifestations and co-existing conditions.
Objective: To assess the effect of calcium pyrophosphate deposition disease (CPPD; chondrocalcinosis) on the axial skeleton and compare it with degenerative disc disease (DDD). Methods: Conventional radiographs (CR) and magnetic resonance imaging (MRI) of patients with CPPD or DDD were retrospectively assessed by 2 independent readers for vacuum phenomena, disc calcification, endplate erosion, osteophytes, disc height changes, and spondylolisthesis. Available follow-up CR were assessed. Results: CR from 140 patients with CPPD (1171 discovertebral units [DVU]) and 99 with DDD (803 DVU) were evaluated (mean [SD] age 74.4 [9.9] vs 71 [6.2] years; 20% vs 20.2% male individuals, respectively). Disc calcification, osteophytes, and erosions were noted significantly more frequently in CPPD vs DDD (16.5% vs 5.2%, 73.5% vs 59.8%, and 13.6% vs 3.2%, respectively; all P ≤ 0.002). Follow-up CR from 29 patients with CPPD and 46 with DDD were available. Significant progression of endplate erosions and osteophytes was seen ( P ≤ 0.02) in both groups. CR follow-up in the CPPD group was shorter than that in DDD (median [IQR] 1.9 [0.6-3.0] vs 3.0 [1.6-4.7] years, respectively; P = 0.03), but CPPD compared with DDD showed more frequent radiographic erosive changes in the thoracic spine (6.8% vs 0.6%; P = 0.02) and lumbar disc calcification (5.8% vs 0.6%; P = 0.01). Conclusion: CPPD is associated with more severe and progressive structural changes in the lower spine compared to DDD. Differentiating CPPD from DDD has clinical implications, influencing both appropriate management strategies and clinical course estimation.